▲ +144.62% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for MeiraGTx in the last 3 months. The average price target is $31.80, with a high forecast of $45.00 and a low forecast of $20.00. The average price target represents a 144.62% upside from the last price of $13.00.
The current consensus among 5 contributing investment analysts is to buy stock in MeiraGTx. This Buy consensus rating has held steady for over two years.
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.